FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1503744211> ?p ?o ?g. }

• W1503744211 endingPage "598" @default.
• W1503744211 startingPage "587" @default.
• W1503744211 abstract "// Huili Li 1,* , Katherine B. Chiappinelli 1,* , Angela A. Guzzetta 1,* , Hariharan Easwaran 1 , Ray-Whay Chiu Yen 1 , Rajita Vatapalli 1 , Michael J. Topper 1 , Jianjun Luo 1 , Roisin M. Connolly 1,2 , Nilofer S. Azad 1 , Vered Stearns 1,2 , Drew M. Pardoll 1 , Nancy Davidson 3 , Peter A. Jones 4 , Dennis J. Slamon 5 , Stephen B. Baylin 1 , Cynthia A. Zahnow 1 , Nita Ahuja 1,6 1 Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA 2 Breast Cancer Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA 3 Department of Medicine, University of Pittsburgh Cancer Institute and UPMC CancerCenter, Pittsburgh, PA 4 Departments of Urology and Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 5 The Jonsson Comprehensive Cancer Center, University of California-Los Angeles 6 Department of Surgery, School of Medicine, Johns Hopkins University, Baltimore, MD, USA * These authors contributed equally to the work Correspondence: Nita Ahuja, email: // Cynthia A. Zahnow, email: // Keywords : Epigenetics, immune, cancers, DNA methyltransferase inhibitor, interferon, methylation, antigen processing Received : February 4, 2014 Accepted : February 16, 2014 Published : February 16, 2014 Abstract Epigenetic therapy is emerging as a potential therapy for solid tumors. To investigate its mechanism of action, we performed integrative expression and methylation analysis of 63 cancer cell lines (breast, colorectal, and ovarian) after treatment with the DNA methyltransferase inhibitor 5-azacitidine (AZA). Gene Set Enrichment Analysis demonstrated significant enrichment for immunomodulatory pathways in all three cancers (14.4-31.3%) including interferon signaling, antigen processing and presentation, and cytokines/chemokines. Strong upregulation of cancer testis antigens was also observed. An AZA IMmune gene set (AIMs) derived from the union of these immunomodulatory pathway genes classified primary tumors from all three types, into “high” and “low” AIM gene expression subsets in tumor expression data from both TCGA and GEO. Samples from selected patient biopsies showed upregulation of AIM genes after treatment with epigenetic therapy. These results point to a broad immune stimulatory role for DNA demethylating drugs in multiple cancers." @default.
• W1503744211 created "2016-06-24" @default.
• W1503744211 creator A5004542056 @default.
• W1503744211 creator A5015491002 @default.
• W1503744211 creator A5019404597 @default.
• W1503744211 creator A5024246556 @default.
• W1503744211 creator A5034057788 @default.
• W1503744211 creator A5040255726 @default.
• W1503744211 creator A5041123333 @default.
• W1503744211 creator A5044143691 @default.
• W1503744211 creator A5054066991 @default.
• W1503744211 creator A5056530735 @default.
• W1503744211 creator A5056613618 @default.
• W1503744211 creator A5058612163 @default.
• W1503744211 creator A5059640571 @default.
• W1503744211 creator A5060219345 @default.
• W1503744211 creator A5066707073 @default.
• W1503744211 creator A5088347458 @default.
• W1503744211 creator A5090054973 @default.
• W1503744211 creator A5091599281 @default.
• W1503744211 date "2014-02-15" @default.
• W1503744211 modified "2023-10-15" @default.
• W1503744211 title "Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers" @default.
• W1503744211 cites W1975486218 @default.
• W1503744211 cites W1983986735 @default.
• W1503744211 cites W2002826921 @default.
• W1503744211 cites W2004630197 @default.
• W1503744211 cites W2021841122 @default.
• W1503744211 cites W2041686632 @default.
• W1503744211 cites W2078844752 @default.
• W1503744211 cites W2079849392 @default.
• W1503744211 cites W2105708117 @default.
• W1503744211 cites W2122953117 @default.
• W1503744211 cites W2128146359 @default.
• W1503744211 cites W2130410032 @default.
• W1503744211 cites W2134539328 @default.
• W1503744211 cites W2135908778 @default.
• W1503744211 cites W2141476381 @default.
• W1503744211 cites W2147516356 @default.
• W1503744211 cites W2149683741 @default.
• W1503744211 cites W2150741140 @default.
• W1503744211 cites W2151783390 @default.
• W1503744211 cites W2154941270 @default.
• W1503744211 cites W2156921232 @default.
• W1503744211 cites W2159104864 @default.
• W1503744211 cites W2159173286 @default.
• W1503744211 cites W2166753727 @default.
• W1503744211 doi "https://doi.org/10.18632/oncotarget.1782" @default.
• W1503744211 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3996658" @default.
• W1503744211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24583822" @default.
• W1503744211 hasPublicationYear "2014" @default.
• W1503744211 type Work @default.
• W1503744211 sameAs 1503744211 @default.
• W1503744211 citedByCount "344" @default.
• W1503744211 countsByYear W15037442112014 @default.
• W1503744211 countsByYear W15037442112015 @default.
• W1503744211 countsByYear W15037442112016 @default.
• W1503744211 countsByYear W15037442112017 @default.
• W1503744211 countsByYear W15037442112018 @default.
• W1503744211 countsByYear W15037442112019 @default.
• W1503744211 countsByYear W15037442112020 @default.
• W1503744211 countsByYear W15037442112021 @default.
• W1503744211 countsByYear W15037442112022 @default.
• W1503744211 countsByYear W15037442112023 @default.
• W1503744211 crossrefType "journal-article" @default.
• W1503744211 hasAuthorship W1503744211A5004542056 @default.
• W1503744211 hasAuthorship W1503744211A5015491002 @default.
• W1503744211 hasAuthorship W1503744211A5019404597 @default.
• W1503744211 hasAuthorship W1503744211A5024246556 @default.
• W1503744211 hasAuthorship W1503744211A5034057788 @default.
• W1503744211 hasAuthorship W1503744211A5040255726 @default.
• W1503744211 hasAuthorship W1503744211A5041123333 @default.
• W1503744211 hasAuthorship W1503744211A5044143691 @default.
• W1503744211 hasAuthorship W1503744211A5054066991 @default.
• W1503744211 hasAuthorship W1503744211A5056530735 @default.
• W1503744211 hasAuthorship W1503744211A5056613618 @default.
• W1503744211 hasAuthorship W1503744211A5058612163 @default.
• W1503744211 hasAuthorship W1503744211A5059640571 @default.
• W1503744211 hasAuthorship W1503744211A5060219345 @default.
• W1503744211 hasAuthorship W1503744211A5066707073 @default.
• W1503744211 hasAuthorship W1503744211A5088347458 @default.
• W1503744211 hasAuthorship W1503744211A5090054973 @default.
• W1503744211 hasAuthorship W1503744211A5091599281 @default.
• W1503744211 hasBestOaLocation W15037442111 @default.
• W1503744211 hasConcept C104317684 @default.
• W1503744211 hasConcept C121608353 @default.
• W1503744211 hasConcept C126322002 @default.
• W1503744211 hasConcept C143998085 @default.
• W1503744211 hasConcept C150194340 @default.
• W1503744211 hasConcept C190727270 @default.
• W1503744211 hasConcept C2779979206 @default.
• W1503744211 hasConcept C41091548 @default.
• W1503744211 hasConcept C502942594 @default.
• W1503744211 hasConcept C530470458 @default.
• W1503744211 hasConcept C54355233 @default.
• W1503744211 hasConcept C71924100 @default.
• W1503744211 hasConcept C74909509 @default.
• W1503744211 hasConcept C86803240 @default.

• next